Transcutaneous CO-oximetry differentiates asthma exacerbation and convalescence in children - 04/08/18
Doi : 10.1016/j.jaci.2018.02.048
David B. Kantor, MD, PhD a, b, Carter R. Petty, MA c, Wanda Phipatanakul, MD, MS b, d, Jonathan M. Gaffin, MD, MMSc e 
a Department of Anesthesia, Boston Children's Hospital, Boston, Mass
c Clinical Research Center, Boston Children's Hospital, Boston, Mass
d Division of Allergy and Immunology, Boston Children's Hospital, Boston, Mass
e Division of Respiratory Diseases, Boston Children's Hospital, Boston, Mass
b Harvard Medical School, Boston, Mass
| Supported by National Institutes of Health (NIH) grants K23AI106945 (PI: J.M.G.), NIH T32 HD040128 (to D.B.K.), NIH K12 HD047349 (to D.B.K.), and NIH K23 HL138162 (to D.B.K.); an American Medical Association Seed Grant (to D.B.K.); and R01 AI 073964, R01 AI 073964-02S1, K24 AI 106822, U01 AI 110397, and U10HL098102 (PI: W.P.). This work was conducted with support from Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH award UL1 TR001102) and financial contributions from Harvard University and its affiliated academic health care centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University, and its affiliated academic health care centers or the NIH. |
|
| Disclosure of potential conflict of interest J. M. Gaffin received a grant from the National Institutes of Health for this work. The rest of these authors declare that they have no relevant conflicts of interest. |
© 2018
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 142 - N° 2
P. 676 - août 2018 Retour au numéro
Article précédent
- Potential role of extracellular vesicle–mediated antigen presentation in Helicobacter pylori hypersensitivity during eradication therapy
- Takamasa Ito, Takashi Shiromizu, Shunsuke Ohnishi, Shotaro Suzuki, Katsuhiro Mabe, Akito Hasegawa, Hideyuki Ujiie, Yasuyuki Fujita, Yuichi Sato, Shuji Terai, Mototsugu Kato, Masahiro Asaka, Takeshi Tomonaga, Hiroshi Shimizu, Riichiro Abe
- Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season
- Alexander Kettner, Gilles DellaCorte, Fréderic de Blay, Lars Jacobsen, Marek Jutel, Margitta Worm, Vincent Charlon, Kim Simonsen, Christophe Reymond, François Spertini
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?